Trial Profile
A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess the Long-Term Effect, Over 1 Year, of Rimonabant 10 mg in Comparison With Rimonabant 20 mg After an Initial Treatment Period of 6 Months With Rimonabant 20 mg in Overweight or Obese Patients.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms MODERATO
- Sponsors Sanofi
- 21 Jan 2022 This trial has been completed in Finland, according to European ClinicalTrials Database record.
- 19 Jun 2009 Actual end date (1 Feb 2009) added as reported by ClinicalTrials.gov.
- 19 Jun 2009 Actual patient number (331) added as reported by ClinicalTrials.gov.